1996.0000 -12.20 (-0.61%)
NSE Jan 19, 2026 09:07 AM
Volume: 309
 

1996.00
-0.61%
Deven Choksey
We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.
Glenmark Pharma has gained 29.47% in the last 1 Year
More from Glenmark Pharmaceuticals Ltd.
Recommended